|本期目录/Table of Contents|

[1]地里呼玛尔·吐鲁洪,王少华.转录因子RFX1上调FZD2促进乳腺癌增殖、侵袭和转移[J].医学研究与战创伤救治(原医学研究生学报),2023,25(3):230-236.[doi:10.3969/j.issn.1672-271X.2023.03.002]
　Dilihumaer Tuluhong,WANG Shaohua.RFX1-induced transcriptional activation of FZD2 accelerates the progression of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(3):230-236.[doi:10.3969/j.issn.1672-271X.2023.03.002]
点击复制

转录因子RFX1上调FZD2促进乳腺癌增殖、侵袭和转移()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第25卷
期数:
2023年3期
页码:
230-236
栏目:
基础研究
出版日期:
2023-08-01

文章信息/Info

Title:
RFX1-induced transcriptional activation of FZD2 accelerates the progression of breast cancer
作者:
地里呼玛尔·吐鲁洪; 王少华
作者单位：210002南京，南京大学医学院附属金陵医院(东部战区总医院)全军普通外科研究所[地里呼玛尔·吐鲁洪、王少华(现在南京医科大学附属妇幼保健院普外科工作）]
Author(s):
Dilihumaer Tuluhong; WANG Shaohua
（Research Institute of General Surgery，Jingling Hospital，Nanjing University School of Medicine/General Hospital of Eastern Theater Command，PLA，Nanjing 210002，Jiangsu，China）
关键词:
乳腺癌; 转录调节因子X1; FZD2; 转录因子
Keywords:
breast cancer; regulator factor X1; FZD2; transcription factor
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2023.03.002
文献标志码:
A
摘要:
目的探讨转录调节因子X1（RFX1）在乳腺癌中的表达及功能，探索其在乳腺癌中的调控机制。方法通过实时荧光定量PCR检测乳腺癌及配对乳腺癌旁组织中RFX1的相对表达量；通过生物信息学、染色质免疫沉淀技术(ChIP)和荧光素酶实验验证转录因子RFX1的靶基因；通过Western blot、CCK8、Transwell和划痕实验明确RFX1对乳腺癌增殖、侵袭、转移和上皮-间质转化（EMT）的影响。结果RFX1在乳腺癌组织中的表达高于癌旁正常组织 (P<0.01)，其表达水平与乳腺癌分期、类型和淋巴结转移状态有关 (P<0.01)。体外实验结果表明RFX1促进乳腺癌细胞的增殖、迁移、转移和EMT过程，差异具有统计学意义 (P<0.05)。生物信息学方法预测RFX1靶向调控FZD2，过表达RFX1使FZD2启动子区转录活性增强(P<0.01)。挽救实验提示外源性下调RFX1后乳腺癌细胞的增殖、侵袭、迁移和上皮-间质转化被FZD2逆转，差异具有统计学意义(P<0.05)。结论RFX1通过上调FZD2促进乳腺癌细胞的增殖、侵袭和转移。这一发现为乳腺癌的治疗提供了新的思路和靶点。
Abstract:
ObjectiveTo explore the expression and function of RFX1 and investigate its regulatory mechanism in breast cancer.MethodsReal-time quantitative PCR was used to detect the relative expression level of RFX1 in cancer and adjacent tissues. Bioinformatics，CHIP，and luciferase experiments were performed to validate the target genes of transcription factor RFX1. Western blot，CCK8，Transwell，and wound healing assay were conducted to elucidate the effects of RFX1 on breast cancer proliferation，invasion，metastasis，and epithelial-mesenchymal transition (EMT).ResultsThe expression of RFX1 in breast cancer tissues was found to be significantly higher than that in adjacent normal tissues (P<0.01). Furthermore，the expression level of RFX1 exhibited a significant correlation with breast cancer stage，type，and lymph node metastasis status (P<0.01). In vitro experiments revealed that RFX1 played a crucial role in promoting the proliferation，migration，metastasis，and EMT process of breast cancer cells (P<0.05). Moreover，bioinformatics analysis predicted that RFX1 exerted its regulatory effects on the target gene FZD2. Overexpression of RFX1 was observed to enhance the transcriptional activity of the FZD2 promoter region (P<0.01). Subsequent rescue experiments demonstrated that the phenotypic changes associated with breast cancer，including proliferation，invasion，migration，and EMT，induced by RFX1 downregulation, which could be reversed by the involvement of FZD2 (P<0.05).ConclusionRFX1 promotes breast cancer cell proliferation，invasion，and metastasis by upregulating FZD2. This finding provides new insights and targets for the treatment of breast cancer.

参考文献/References:

[1]Siegel RL，Milier KD，Fuchs HE，et al. Cancer statistics，2022[J].CA Cancer J Clin，2022，72(1)：7-33.
[2]Kawiak A. Molecular Research and Treatment of Breast Cancer[J].Int J Mol Sci，2022，23(17).
[3]王文艺，刘佳静，李晓璐，等. HMGB3在乳腺癌中的表达及意义分析[J].医学研究与战创伤救治，2023，36(1)：56-63.
[4]Castro-mondragon JA，Riudavets-puig R，Rauluseviciute I，et al. JASPAR 2022：the 9th release of the open-access database of transcription factor binding profiles[J].Nucleic Acids Res，2022，50(D1)：D165-D173.
[5]Issac J，Raveendran PS，Das AV. RFX1：a promising therapeutic arsenal against cancer[J].Cancer Cell Int，2021，21(1)：253.
[6]Du P，Gao K，Cao Y，et al. RFX1 downregulation contributes to TLR4 overexpression in CD14(+) monocytes via epigenetic mechanisms in coronary artery disease[J].Clin Epigenetics，2019，11(1)：44.
[7]Guo L，Liu D. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma[J].Eur J Med Res，2022，27(1)：164.
[8]林慧，陈佳菁，郭志锋，等. miR-9-5p在乳腺癌组织中的表达与生物信息学分析[J].东南国防医药，2023，25(1)：23-27.
[9]Weidemuller P，Kholmatov M，Petsalaki E，et al. Transcription factors：Bridge between cell signaling and gene regulation[J].Proteomics，2021，21(23-24)：e2000034.
[10]Sahu B，Hartonen T，Pihlajamaa P，et al. Sequence determinants of human gene regulatory elements[J].Nat Genet，2022，54(3)：283-294.
[11]Sugiaman-trapman D，Vitezic M，Jouhilahti EM，et al. Characterization of the human RFX transcription factor family by regulatory and target gene analysis[J].BMC Genomics，2018，19(1)：181.
[12]Schwab K，Coronel L，Riege K，et al. Multi-omics analysis identifies RFX7 targets involved in tumor suppression and neuronal processes[J].Cell Death Discov，2023，9(1)：80.
[13]Si D，Yin F，Peng J，et al. High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas[J].Cancer Manag Res，2020,12：769-775.
[14]Xu J，Zhang J，MaO QF，et al. The Interaction Between Autophagy and JAK/STAT3 Signaling Pathway in Tumors[J].Front Genet，2022，13：880359.doi: 10.3389/fgene.2022.880359.
[15]Liu Y，Jiang P，Wang G，et al. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma[J].Eur J Surg Oncol，2018，44(7)：1087-1093.
[16]Jia S，Yang S，Du P，et al. Regulatory Factor X1 Downregulation Contributes to Monocyte Chemoattractant Protein-1 Overexpression in CD14+ Monocytes via Epigenetic Mechanisms in Coronary Heart Disease[J].Front Genet，2019，10：1098.doi: 10.3389/fgene.2019.01098.
[17]Liu G，Ruan G，HUANG M，et al. Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities[J].Aging (Albany NY)，2020，12(1)：178-192.
[18]Hamidi AA，Khalili-tanha G，Nasrpour navaei Z，et al. Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells：an overview[J].Cancer Cell Int，2022，22(1)：71.
[19]Chattopadhyay I，Ambati R，Gundamaraju R. Exploring the Crosstalk between Inflammation and Epithelial-Mesenchymal Transition in Cancer[J].Mediators Inflamm，2021.doi: 10.1155/2021/9918379.
[20]Tuluhong D，Chen T，Wang J，et al. FZD2 promotes TGF-beta-induced epithelial-to-mesenchymal transition in breast cancer via activating notch signaling pathway[J].Cancer Cell Int，2021，21(1)：199.

相似文献/References:

[1]邵明永,丁庆莉,高 纯,等.CA125和CA153联合检测对乳腺癌的诊治价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
　SHAO Ming-yong,DING Qing-li,GAO Chun,et al.Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(3):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
[2]蒋 静,程珠玲.乳腺肿瘤患者心理护理的对策[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):553.
[3]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(3):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
[4]朱成宾,潘玉琴,何帮顺.微小RNA多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
　ZHU Cheng-bin,PAN Yu-qin,HE Bang-shun..Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(3):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
[5]刘 彧,童清平,连 娟,等.乳腺癌弹性超声特征与分子生物学指标的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
　LIU Yu,TONG Qing-ping,LIAN Juan,et al.Relationship between ultrasonic elastography features and ER， PR， Her-2 and Ki67 expression in molecular biology of breast[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(3):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
[6]陈涛,王璇,程凯,等.CD47在乳腺癌及癌旁组织中的表达及其意义[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
　CHEN Tao,WANG Xuan,CHENG Kai,et al.Expression and significance of CD47 in breast cancer and pericancerous tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(3):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
[7]陈雨秋,周国华,顾军.半乳糖凝集素3与乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
　CHEN Yu-qiu,ZHOU Guo-hua,GU Jun.Research progress of galectin-3 and breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(3):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
[8]地里呼玛尔·吐鲁洪,李欣芳,王少华.HR+/HER2-乳腺癌内分泌治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
　Dilihumaer Tuluhong,LI Xin-fang,WANG Shao-hua.The trend of endocrine therapeutic approach in HR+/HER2-breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(3):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
[9]何小芳,周敏,熊朝月,等.乳腺癌超声征象及其术后复发的危险因素分析[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
　HE Xiao-fang,ZHOU Min,XIONG Chao-yue,et al.Ultrasonicsigns of breast cancer and analysis of risk factors for postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
[10]吴勤研,蓝晓红,吴波,等.基于生物信息技术分析人参皂苷防治乳腺癌的作用机制[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
　WU Qin-yan,LAN Xiao-hong,WU Bo,et al.Analysis of the mechanism of action of ginsenosides in preventing and treating breast cancer based on bioinformatics technology[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(3):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]

备注/Memo

备注/Memo:
基金项目：南京军区医药卫生科研基金课题（ZD33）
更新日期/Last Update: 2023-08-24